PBAC's latest decision on Olanzapine pamoate monohydrate: Recommended with restriction (2009). Considered for treatment of schizophrenia in adult patients who can be stabilised with oral olanzapine.
PBAC outcome
Recommended with restriction
Authority Required (Streamlined)
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2009
Submissions
1
2009 → 2009
Eligible population
adult patients who can be stabilised with oral olanzapine and are treated for schizophrenia
Therapy area
Psychiatry
Line of therapy
Not applicable
Evidence base
RCT | Single-arm
Primary endpoint
PANSS total score, exacerbation rates of schizophrenia
Key trials
HGJZ, Kane 2003, HGKA
Comparator
risperidone modified release injection
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis performed; no ICER calculated